Description

Diazepam 10 mg (Valium) Tablets

Valium 10 mg is a high-strength oral formulation of diazepam, a classic long-acting benzodiazepine. It acts by potentiating the inhibitory neurotransmitter gamma-aminobutyric acid ($\text{GABA}$) at $\text{GABA}_A$ receptor sites throughout the central nervous system. This enhances neuronal membrane permeability to chloride ions, producing pronounced anxiolytic, skeletal muscle relaxant, anticonvulsant, and sedative properties.

Product Overview

Primary Indications

Diazepam 10 mg is administered under medical guidance for:

• Severe Anxiety Disorders: Short-term management of acute, severe anxiety states and agitation unresponsive to lower dosages.

• Acute Alcohol Withdrawal: Alleviation of acute agitation, tremor, impending delirium tremens, and hallucinosis.

• Skeletal Muscle Spasm: Adjunctive relief of reflex muscle spasms caused by local pathology (inflammation of muscles/joints or secondary to trauma) or spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia).

• Convulsive Disorders: Adjunctive therapy in the management of recurrent convulsive seizures (frequently paired with standard anticonvulsant regimens).

• Pre-Procedural Sedation: Preoperative medication to relieve tension and anxiety in surgical candidates.

Key Information & Precautions

• Dosage & Titration: Dosage must be individualized. Because 10 mg represents the highest standard single-tablet oral strength for diazepam, therapy is typically initiated at lower doses (2 mg to 5 mg) and escalated only as clinically indicated.

• Cumulative Effects: Due to its prolonged elimination half-life and active metabolites, repeated dosing leads to substantial tissue accumulation, increasing the risk of over-sedation, especially in geriatric patients or those with impaired hepatic clearance.

• Dependence & Addiction Risk: High-potency, long-term administration carries a substantial risk of physical dependence, tolerance, and misuse. Treatment courses should be kept as short as clinically feasible (generally 2 to 4 weeks).

• Severe Withdrawal Hazard: Abrupt discontinuation can trigger life-threatening withdrawal complications, including status epilepticus, delirium, psychosis, severe tremors, and rebound anxiety. A gradual, medically managed dosage taper is strictly mandatory.

• Black Box Warnings & Critical Interactions:

  • Concomitant Opioid / Alcohol Use: Co-administration with opioids, alcohol, or other CNS depressants markedly increases the risk of profound sedation, respiratory depression, coma, and death.

  • Psychomotor Impairment: Causes marked somnolence, ataxia, and slowed reaction times. Operating motor vehicles or machinery is contraindicated until patient stabilization is established.